Sensus Healthcare, Inc. (SRTS)

Over the past six months, Sensus Healthcare's stock price has been impacted by several events. The company reported missed consensus estimates for both Q1 2026 and Q4 2025 financial results, with the absence of sales from its largest customer affecting the Q4 results. In March 2026, Sensus Healthcare filed a lawsuit against SkinCure Oncology for breach of contract. The company introduced "Sensus Link" and launched "Sensus Healthcare Financial Services" in February 2026. Dedicated CPT codes for SRT to treat non-melanoma skin cancer were established, effective January 1, 2026. Insider buying activity has been noted. The share price experienced a decline of 17.31% between April 28, 2025, and April 24, 2026, and has traded between $2.82 and $5.92 over the past 52 weeks.

Explicit information detailing predictable monthly or quarterly demand seasonality for Sensus Healthcare's products and services is not readily available. Demand can be influenced by broader economic factors, as seen in 2023 when customers deferred purchases due to macroeconomic conditions. The company anticipates continued growth, as indicated by increased finished goods inventory in 2024. Healthy utilization trends within its "Fair Deal Agreement" program and increasing FDA treatment volumes suggest that program adoption and growing awareness contribute to demand. The introduction of new CPT codes for SRT is expected to strengthen adoption by leveling the playing field for reimbursement.

Sensus Healthcare, Inc. specializes in non-invasive and minimally-invasive treatments for skin conditions, including oncological and non-oncological issues. The company is a global pioneer in developing non-invasive treatments for skin cancer and keloids, utilizing superficial radiotherapy (SRT and IG-SRT). Its major products include the SRT-100™, SRT-100 Vision™, and SRT-100+™ systems, offering non-surgical alternatives for treating skin cancers and keloids. The company also provides a Sentinel service program, in-office laser rental services, a Transdermal Infusion system, and disposable radiation safety items. Sensus Healthcare markets its products primarily to private dermatology practices and radiation oncologists.

Sensus Healthcare's revenue is predominantly generated from customers in the United States, but it has a global presence with SRT units installed in 21 countries as of December 31, 2025. The company has received regulatory clearances in the U.S., Europe, China, Canada, and Russia.

Sensus Healthcare maintains a strong brand reputation, particularly in its niche, and is recognized as a global pioneer in non-invasive treatments for skin cancer and keloids. Its SRT technology has been used to treat nearly one million patients worldwide. The establishment of dedicated CPT codes for superficial radiotherapy for non-melanoma skin cancer and clinical studies demonstrating the efficacy of Sensus' SRT have bolstered its reputation. The company was also named to TIME's America's Growth Leaders of 2026. However, the lawsuit filed against SkinCure Oncology could potentially impact its reputation.

Sensus Healthcare, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 7.89% to 29% of the company's stock is held by institutional investors, 9.13% by insiders, and a significant portion, around 53.3% to 69.68%, by the general public and individual investors. Major institutional owners include Vanguard Group Inc., Pacific Ridge Capital Partners, LLC, and Dimensional Fund Advisors Lp. Key individual owners and insiders include Joseph C. Sardano, Edwin Solot, Michael Sardano, and Eric Sachetta.